Deerfield Management

Founded in 2018, Intus Care develops a platform that connects home care providers with patients. Its application uses machine learning to predict hospital readmissions and risks, enabling efficient tracking of care providers and high-risk patient identification.

Lumeris is a company focused on transforming accountable care delivery by providing operational support, technology, and consulting services to health systems, payers, and providers. It offers a value-based care managed services platform that enhances clinical and financial outcomes through guidance and advanced risk management capabilities. By collaborating with healthcare organizations across the country, Lumeris helps them design, build, and optimize accountable care models aimed at improving quality, reducing costs, and enhancing patient and physician satisfaction. The company's innovative solutions are designed to yield better health outcomes for patients while addressing the challenges associated with chronic diseases, ultimately supporting the overarching goals of improved quality, cost efficiency, and satisfaction in the healthcare system.

Vesta Healthcare is a technology and clinical services organization based in New York, specializing in connecting caregivers to care teams through its innovative health care platform. The company offers 24/7 telehealth support aimed at caregivers and care recipients, particularly focusing on high-need, frail senior populations. Vesta partners with home care agencies, health plans, and healthcare providers to develop value-based population health programs that prioritize clinical quality and improved health outcomes. Founded in 2008 and originally known as Hometeam Technologies, Inc., Vesta Healthcare has established itself as a leader in enhancing caregiver insights and facilitating personalized engagement in the healthcare setting.

Reprieve Cardiovascular, Inc. is a medical device company based in Milford, Massachusetts, established in 2018. The company specializes in developing innovative fluid management technologies aimed at treating congestive heart failure. Its flagship product, the Reprieve technology, offers a solution for clinicians to precisely control the fluid volume in patients suffering from acute decompensated heart failure (ADHF). This ability to manage fluid levels is essential for improving cardiac care and assisting in the decongestion process for these patients. Reprieve Cardiovascular operates as a subsidiary of CardioRenal Systems, Inc.

Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

Founded in 2018, Intus Care develops a platform that connects home care providers with patients. Its application uses machine learning to predict hospital readmissions and risks, enabling efficient tracking of care providers and high-risk patient identification.

COTA, Inc. is a Boston-based company that specializes in developing a platform designed to provide data and insights related to cancer patients, aimed at guiding treatment decisions. Founded in 2011 by a team of doctors, engineers, and data scientists, COTA utilizes proprietary technology and advanced analytics to transform fragmented electronic health record (EHR) data into cohesive, research-grade information. This platform supports oncology practices and cancer centers by identifying variations in care, thus enabling the design of effective treatment programs and payment models. COTA's solutions serve a diverse range of stakeholders, including healthcare providers, payers, life sciences companies, and the FDA, ultimately striving to enhance patient outcomes and reduce healthcare costs associated with cancer care.

UTR Therapeutics Inc is a biotechnology company focused on developing treatments for aggressive cancers driven by the overexpression of the c-MYC gene. The company, spun out from City University of New York and Harvard Medical School, specializes in researching and developing therapeutics that target and degrade specific gene transcripts involved in tumor progression. Their primary focus is on cancers like triple negative breast cancer, medulloblastoma, and osteosarcoma, aiming to provide clinicians with treatments that directly act on cancer-causing genetic expressions.

Vibliome Therapeutics, Inc. is a biotechnology company based in Bozeman, Montana, established in 2017. The company specializes in researching and developing non-hormonal birth control options for men, utilizing homeodomain-interacting protein kinase 4 (HIPK4). Additionally, Vibliome focuses on creating small molecule kinase inhibitors aimed at treating various cancers and inflammatory diseases. Their innovative approach involves a systematic methodology that enables the development of inhibitors with unique selectivity profiles, leveraging the extensive array of over 500 kinases present in the human genome. By analyzing the design of Type II inhibitors, Vibliome aims to lock kinase targets in an inactive conformation, facilitating the identification of unique similarities and differences between kinases, which supports the advancement of therapeutics for cancer and other chronic conditions.

ConcertoCare is dedicated to delivering primary and complex care to seniors and other adult patients with unmet health and social needs. The company employs a tech-enabled, value-based care model that features three distinct in-home care approaches, all supported by its proprietary population health and analytics platform. ConcertoCare's interdisciplinary teams, led by experienced professionals in home-based geriatric medicine, digital health, palliative care, and healthcare analytics, utilize clinical decision support tools to enhance patient care. This innovative model aims to lower overall healthcare costs while improving health outcomes for its patients.

V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.

DeepSight Technology enhances diagnostic medical imaging by advancing ultrasound technology. It offers proprietary sensing technology and customizable systems, integrating with industry partners to provide clinicians with deeper insights for improved patient outcomes.

Novocardia is dedicated to enhancing the delivery of cardiovascular care, aiming to support patients with heart and vascular diseases in achieving longer and healthier lives. The company operates a cardiovascular care delivery network that emphasizes improving the quality and value of care provided to patients. By fostering collaborative relationships with health plans and primary care partners, Novocardia facilitates the transition to value-based care. Its platform encompasses various capabilities, including the implementation of quality and process improvement initiatives and technology-enabled care delivery, thereby equipping cardiologists with the necessary tools to better serve their patients.

CareMax is a technology-enabled care platform focused on delivering value-based care and chronic disease management for seniors. The company operates a network of medical centers that provide a wide range of healthcare and social services. Additionally, CareMax has developed a proprietary software and services platform that offers data, analytics, and rules-based decision tools to assist physicians in their practice. This integrated approach aims to enhance the quality of care for seniors while managing their healthcare needs effectively across the United States.

Vesta Healthcare is a technology and clinical services organization based in New York, specializing in connecting caregivers to care teams through its innovative health care platform. The company offers 24/7 telehealth support aimed at caregivers and care recipients, particularly focusing on high-need, frail senior populations. Vesta partners with home care agencies, health plans, and healthcare providers to develop value-based population health programs that prioritize clinical quality and improved health outcomes. Founded in 2008 and originally known as Hometeam Technologies, Inc., Vesta Healthcare has established itself as a leader in enhancing caregiver insights and facilitating personalized engagement in the healthcare setting.

Twill is a developer of a software-enabled healthcare platform focused on enhancing mental and physical wellness. The company offers a web and mobile-based technology that evaluates users' happiness through both subjective and objective assessments. In addition, Twill provides a variety of programs and games designed to promote healthier mindsets. This approach enables individuals, employers, and care delivery systems to effectively address issues such as stress, depression, anxiety, and social isolation, which are often associated with chronic illness. By integrating these tools, Twill aims to support users in achieving improved overall well-being.

Springtide Child Development, Inc. is a Trumbull, Connecticut-based provider of child development services tailored for children aged 2 to 18 with autism and other developmental challenges. Established in 2018, the company offers a range of personalized and holistic treatment plans designed to address various needs. Its interdisciplinary team of specialists provides services including Applied Behavior Analysis (ABA) therapy, speech therapy, occupational therapy, physical therapy, and social skills development. The clinic also focuses on language acquisition and functional living skills, ensuring a comprehensive approach to support each child's growth and progress. By closely monitoring individual development, Springtide Child Development aims to help children reach their full potential.

V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.

Reprieve Cardiovascular, Inc. is a medical device company based in Milford, Massachusetts, established in 2018. The company specializes in developing innovative fluid management technologies aimed at treating congestive heart failure. Its flagship product, the Reprieve technology, offers a solution for clinicians to precisely control the fluid volume in patients suffering from acute decompensated heart failure (ADHF). This ability to manage fluid levels is essential for improving cardiac care and assisting in the decongestion process for these patients. Reprieve Cardiovascular operates as a subsidiary of CardioRenal Systems, Inc.

Farapulse, Inc. is a medical technology company based in Menlo Park, California, that specializes in the development and commercialization of catheter-based tools aimed at treating atrial fibrillation. Founded in 2012 and formerly known as Iowa Approach, Inc., the company offers an innovative product called FARAWAVE, which features advanced tissue-selective pulsed field ablation (PFA) therapy. This therapy is designed for both endocardial and epicardial approaches to atrial fibrillation ablation. Farapulse's portfolio includes a variety of catheters, such as over-the-wire, deflectable, linear, and circumferential lesion catheters, enabling physicians to effectively isolate pulmonary veins and enhance the safety, accessibility, and cost-effectiveness of atrial fibrillation treatments for patients.

Vesta Healthcare is a technology and clinical services organization based in New York, specializing in connecting caregivers to care teams through its innovative health care platform. The company offers 24/7 telehealth support aimed at caregivers and care recipients, particularly focusing on high-need, frail senior populations. Vesta partners with home care agencies, health plans, and healthcare providers to develop value-based population health programs that prioritize clinical quality and improved health outcomes. Founded in 2008 and originally known as Hometeam Technologies, Inc., Vesta Healthcare has established itself as a leader in enhancing caregiver insights and facilitating personalized engagement in the healthcare setting.

Contessa, headquartered in Nashville, specializes in Home Recovery Care, a risk-based model that delivers inpatient-level care in patients' homes. Established in 2015, Contessa uses its proprietary health informatics platform to facilitate safe, affordable, and outcome-improving home care. The company offers turnkey solutions, providing upfront savings for health plans, enabling healthcare systems to reinvent their care delivery model by treating patients outside the hospital, and enhancing patient experience through better physician support.

Nkarta Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company aims to harness the inherent power of NK cells to target and destroy tumor cells, offering a potent and better-tolerated alternative to traditional T-cell therapies for a broad range of cancer indications.

Ribon Therapeutics, Inc. is a biotechnology company founded in 2015 and headquartered in Lexington, Massachusetts. The company focuses on developing novel therapeutics that target monoPARP proteins, which are critical regulators of cancer cell survival mechanisms. By leveraging insights from its scientific founders, Ribon is establishing a proprietary drug discovery platform aimed at investigating the molecular actions and biological functions of a specific subset of the PARP protein family. This platform enables Ribon to create a pipeline of innovative small molecule inhibitors designed to disrupt the fundamental survival capabilities of cancer cells under stress. In addition to cancer treatment, the company's research may have implications for addressing other diseases. Ribon is supported by notable life science investors, which enhances its capacity to advance its therapeutic developments.

Allogene Therapeutics is a clinical-stage biotech company focused on immuno-oncology, developing genetically engineered allogeneic T-cell therapies for cancer. The company builds a pipeline of off-the-shelf donor-derived CAR-T products using gene-editing and proprietary cell-manufacturing technologies to enable broader patient eligibility and scalable production. Its programs include UCART19 for relapsed or refractory acute lymphoblastic leukemia and other allogeneic CAR-T candidates targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue is primarily generated from collaborations and licensing agreements.

Orchard Therapeutics is a UK-based biopharmaceutical company dedicated to developing and commercializing innovative gene therapies for rare diseases. Its core focus is autologous ex vivo gene therapy, transforming hematopoietic stem cells into a gene-modified drug product for single-administration treatments. The company's portfolio includes Strimvelis, approved by the EMA in 2016, and several programs in advanced registrational studies across various disease areas.

Cureatr Inc. is a New York-based company that specializes in mobile care coordination solutions for healthcare providers. Founded in 2011, it offers a cloud-based medication management software designed to optimize patient care, particularly focusing on post-discharge medication reconciliation. The platform combines HIPAA-secure text messaging with workflow navigation tools, facilitating communication and coordination among healthcare professionals. Cureatr's software features an inbuilt dashboard that curates and analyzes patients' medication history, enabling providers to respond to real-time events and improve their interactions with patients. By streamlining these processes, Cureatr enhances the overall quality of patient care.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, established in 2014. It specializes in the discovery and development of innovative therapies aimed at treating liver and gastrointestinal diseases. The company is advancing a pipeline of drug candidates, with a primary focus on the farnesoid X receptor (FXR), a key target in managing various liver and GI disorders. Its lead candidates, MET409 and MET642, are currently in clinical trials to evaluate their efficacy in treating non-alcoholic steatohepatitis. Additionally, Metacrine collaborates with Novo Nordisk A/S to explore further research opportunities related to fibroblast growth factor 1. The company is committed to developing best-in-class therapies to improve patient outcomes in these challenging medical areas.

V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.

Farapulse, Inc. is a medical technology company based in Menlo Park, California, that specializes in the development and commercialization of catheter-based tools aimed at treating atrial fibrillation. Founded in 2012 and formerly known as Iowa Approach, Inc., the company offers an innovative product called FARAWAVE, which features advanced tissue-selective pulsed field ablation (PFA) therapy. This therapy is designed for both endocardial and epicardial approaches to atrial fibrillation ablation. Farapulse's portfolio includes a variety of catheters, such as over-the-wire, deflectable, linear, and circumferential lesion catheters, enabling physicians to effectively isolate pulmonary veins and enhance the safety, accessibility, and cost-effectiveness of atrial fibrillation treatments for patients.

ConcertoCare is dedicated to delivering primary and complex care to seniors and other adult patients with unmet health and social needs. The company employs a tech-enabled, value-based care model that features three distinct in-home care approaches, all supported by its proprietary population health and analytics platform. ConcertoCare's interdisciplinary teams, led by experienced professionals in home-based geriatric medicine, digital health, palliative care, and healthcare analytics, utilize clinical decision support tools to enhance patient care. This innovative model aims to lower overall healthcare costs while improving health outcomes for its patients.

Lumeris is a company focused on transforming accountable care delivery by providing operational support, technology, and consulting services to health systems, payers, and providers. It offers a value-based care managed services platform that enhances clinical and financial outcomes through guidance and advanced risk management capabilities. By collaborating with healthcare organizations across the country, Lumeris helps them design, build, and optimize accountable care models aimed at improving quality, reducing costs, and enhancing patient and physician satisfaction. The company's innovative solutions are designed to yield better health outcomes for patients while addressing the challenges associated with chronic diseases, ultimately supporting the overarching goals of improved quality, cost efficiency, and satisfaction in the healthcare system.

Ribon Therapeutics, Inc. is a biotechnology company founded in 2015 and headquartered in Lexington, Massachusetts. The company focuses on developing novel therapeutics that target monoPARP proteins, which are critical regulators of cancer cell survival mechanisms. By leveraging insights from its scientific founders, Ribon is establishing a proprietary drug discovery platform aimed at investigating the molecular actions and biological functions of a specific subset of the PARP protein family. This platform enables Ribon to create a pipeline of innovative small molecule inhibitors designed to disrupt the fundamental survival capabilities of cancer cells under stress. In addition to cancer treatment, the company's research may have implications for addressing other diseases. Ribon is supported by notable life science investors, which enhances its capacity to advance its therapeutic developments.

Rhythm Metabolic is the subsidiary of Rhythm Pharmaceuticals that develops setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway. It was established in 2013 and is headquartered in Boston, Massachusetts.

Cureatr Inc. is a New York-based company that specializes in mobile care coordination solutions for healthcare providers. Founded in 2011, it offers a cloud-based medication management software designed to optimize patient care, particularly focusing on post-discharge medication reconciliation. The platform combines HIPAA-secure text messaging with workflow navigation tools, facilitating communication and coordination among healthcare professionals. Cureatr's software features an inbuilt dashboard that curates and analyzes patients' medication history, enabling providers to respond to real-time events and improve their interactions with patients. By streamlining these processes, Cureatr enhances the overall quality of patient care.

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company dedicated to developing innovative treatments for severe neurological diseases. The company’s lead clinical candidate, VY-AADC, is currently undergoing an open-label Phase 1b trial for Parkinson’s disease. Its diverse preclinical pipeline includes candidates for various conditions, such as VY-SOD102 for amyotrophic lateral sclerosis, VY-HTT01 for Huntington’s disease, VY-FXN01 for Friedreich’s ataxia, and programs targeting tauopathies and synucleinopathies, which encompass Alzheimer’s disease and related disorders. Voyager Therapeutics employs a gene therapy platform known as TRACER, which enables the engineering and optimization of adeno-associated virus (AAV) therapies aimed at producing lasting therapeutic effects from a single treatment. The company collaborates with several institutions, including the University of Massachusetts and ClearPoint Neuro, as well as industry partners like Brammer Bio and Fujifilm Diosynth Biotechnologies, to enhance its gene therapy initiatives. Founded in 2013 and headquartered in Cambridge, Massachusetts, Voyager Therapeutics is committed to addressing unmet medical needs in the central nervous system.

Assertio is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. Established in 1995, the company markets four FDA-approved products: Gralise for managing postherpetic neuralgia, Cambia for treating migraines, Zipsor for relieving mild to moderate acute pain, and Lazanda for managing breakthrough cancer pain.

Epion Health, Inc. is a developer of a patient engagement platform that offers a range of mobile health applications and content through a cloud-based solution. Founded in 2011 and headquartered in Roseland, New Jersey, the company enables patients to access health-related information on their smartphones or mobile devices, helping them learn about their health and prepare for medical visits. Additionally, the platform provides physicians with access to essential health information, including pre-loaded medical applications such as drug references, dosage calculators, and health assessments. By facilitating communication between patients and healthcare providers, Epion Health aims to enhance patient care and improve overall efficiency in the healthcare continuum.

OMNIlife science, Inc. specializes in the design, manufacture, and distribution of orthopedic devices, focusing on joint replacement solutions. Founded in 1999 and headquartered in East Taunton, Massachusetts, the company offers a range of products, including orthopedic implants for knees and hips, as well as advanced robotic navigation technology known as OMNINAV, which enhances the precision of total knee surgeries tailored to individual patients. The company serves a diverse international market, including regions such as South Africa, Switzerland, Turkey, and several European countries, distributing its products through various distributors. OMNIlife science operates as a subsidiary of Orthopaedic Synergy, Inc.

Wellfount Corp., established in 2006 and headquartered in Indianapolis, Indiana, specializes in providing pharmacy services to nursing facilities. The company offers a range of services including utilization and compliance reviews, multi-dose and compliance packaging, daily deliveries, intravenous therapy, and customized invoicing. Wellfount also provides EHR application integration and medical record services, along with medications and consulting services. Through its innovative technologies, the company aims to improve patient care quality and reduce costs by streamlining medication management processes in long-term care facilities.

Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company founded in 2007 and based in New Haven, Connecticut. The company specializes in the discovery and development of monoclonal antibody drugs that target receptor tyrosine kinases (RTKs), which play a crucial role in various cancers and other diseases. Its lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK and is currently undergoing Phase I clinical trials for adult patients with advanced solid tumors. Additionally, Kolltan is developing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory conditions, as well as KIT-ADC, an antibody-drug conjugate for oncology applications. The company is also engaged in various research programs focused on RTK targets, building on foundational discoveries made in collaboration with leading academic laboratories. As of late 2016, Kolltan Pharmaceuticals operates as a subsidiary of Celldex Therapeutics, Inc.

Auspex Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for orphan diseases, particularly those involving involuntary movement disorders. The company’s pipeline features product candidates aimed at addressing significant unmet medical needs, including hyperkinetic movement disorders such as chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome. Auspex Pharmaceuticals specializes in creating deuterated analogs of clinically-validated drugs, enhancing existing therapies across various therapeutic areas, including respiratory disease and inflammation. Through its focused approach, the company seeks to provide effective treatment options for patients suffering from these challenging conditions.

New American Therapeutics, Inc. is a privately held specialty pharmaceutical company located in Parsippany, New Jersey. The company focuses on acquiring, marketing, and developing products within select therapeutic areas, aiming to enhance patients' lives through the commercialization of innovative pharmaceutical solutions. Its primary area of expertise is in cardiovascular diseases, where it specializes in creating advanced therapeutic drugs. By prioritizing the development of user-friendly pharmaceutical forms, New American Therapeutics seeks to provide effective treatments that facilitate easier management of cardiovascular conditions for patients.

Exelixis is a biopharmaceutical company dedicated to discovering, developing, and commercializing therapies for cancer. Its primary product, cabozantinib, is marketed as Cometriq for metastatic medullary thyroid cancer and Cabometyx for kidney and liver cancers. Exelixis also offers Cotellic in collaboration with Roche for melanoma treatment.

NitroMed is an emerging pharmaceutical company that discovers, develops and seeks to commercialize proprietary pharmaceuticals based on the therapeutic benefits of the naturally-occurring molecule nitric oxide. NitroMed is conducting a late-stage confirmatory trial of our lead nitric oxide-enhancing drug, BiDil, for the treatment of heart failure in African Americans.

Exelixis is a biopharmaceutical company dedicated to discovering, developing, and commercializing therapies for cancer. Its primary product, cabozantinib, is marketed as Cometriq for metastatic medullary thyroid cancer and Cabometyx for kidney and liver cancers. Exelixis also offers Cotellic in collaboration with Roche for melanoma treatment.

Dynavax Technologies Corporation is a biopharmaceutical company specializing in the development and commercialization of innovative vaccines. Its flagship product, HEPLISAV-B, is a recombinant adjuvanted hepatitis B vaccine approved for use in adults aged 18 years and older, targeting all known subtypes of the hepatitis B virus. The company utilizes its proprietary Toll-like Receptor Immune Modulation Platform to enhance both innate and adaptive immune responses. Dynavax is actively advancing its immuno-oncology portfolio and has several development-stage products, including SD-101 and DV281, aimed at various cancer indications. In addition, the company engages in multiple research collaborations to develop adjuvanted vaccines for infectious diseases, including COVID-19, partnering with organizations such as Clover Biopharmaceuticals, the University of Queensland, and the Coalition for Epidemic Preparedness Innovations. Established in 1996 and headquartered in Emeryville, California, Dynavax continues to expand its role in vaccine development.